HR and triple-negative breast carcinoma: A total of 321 (54.5%) patients were HR+/HER2-, 111 (18.8%) were HR+/HER2+, and 64 (10.9%) were HR-/HER2+, while 68 (11.5%) had triple-negative breast cancer (TNBC, HR-/HER2-).